US Bancorp DE boosted its position in Thermo Fisher Scientific Inc (NYSE:TMO) by 4.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 229,678 shares of the medical research company’s stock after buying an additional 9,408 shares during the period. US Bancorp DE owned approximately 0.06% of Thermo Fisher Scientific worth $40,071,000 as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. BlackRock Inc. raised its stake in shares of Thermo Fisher Scientific by 2,692.1% in the first quarter. BlackRock Inc. now owns 22,988,885 shares of the medical research company’s stock worth $3,531,095,000 after buying an additional 22,165,530 shares in the last quarter. C WorldWide Group Holding A S raised its stake in shares of Thermo Fisher Scientific by 997.1% in the first quarter. C WorldWide Group Holding A S now owns 1,950,049 shares of the medical research company’s stock worth $299,527,000 after buying an additional 1,772,300 shares in the last quarter. Veritas Asset Management LLP bought a new stake in shares of Thermo Fisher Scientific during the first quarter worth approximately $175,795,000. Vanguard Group Inc. raised its stake in shares of Thermo Fisher Scientific by 2.7% in the first quarter. Vanguard Group Inc. now owns 25,971,301 shares of the medical research company’s stock worth $3,989,193,000 after buying an additional 695,079 shares in the last quarter. Finally, Renaissance Technologies LLC raised its stake in shares of Thermo Fisher Scientific by 68.8% in the first quarter. Renaissance Technologies LLC now owns 1,373,044 shares of the medical research company’s stock worth $210,900,000 after buying an additional 559,400 shares in the last quarter. 87.60% of the stock is currently owned by institutional investors and hedge funds.
Thermo Fisher Scientific Inc (NYSE:TMO) opened at 172.57 on Friday. Thermo Fisher Scientific Inc has a one year low of $139.07 and a one year high of $182.87. The company has a market capitalization of $67.32 billion, a price-to-earnings ratio of 30.06 and a beta of 1.06. The firm’s 50-day moving average price is $176.71 and its 200 day moving average price is $166.56.
Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, July 26th. The medical research company reported $2.30 EPS for the quarter, topping analysts’ consensus estimates of $2.27 by $0.03. Thermo Fisher Scientific had a net margin of 11.80% and a return on equity of 15.97%. The business had revenue of $5 billion during the quarter, compared to the consensus estimate of $4.92 billion. During the same quarter in the previous year, the firm posted $2.03 EPS. The firm’s revenue was up 10.2% on a year-over-year basis. On average, equities research analysts expect that Thermo Fisher Scientific Inc will post $9.24 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Monday, October 16th. Shareholders of record on Friday, September 15th will be given a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 0.35%. The ex-dividend date of this dividend is Thursday, September 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.45%.
TMO has been the subject of a number of recent research reports. Cantor Fitzgerald initiated coverage on Thermo Fisher Scientific in a report on Thursday, May 18th. They set an “overweight” rating and a $194.00 price objective for the company. Barclays PLC set a $175.00 price objective on Thermo Fisher Scientific and gave the stock a “buy” rating in a report on Wednesday, April 26th. Cowen and Company reissued an “outperform” rating and set a $185.00 price objective (up from $175.00) on shares of Thermo Fisher Scientific in a report on Saturday, April 29th. Citigroup Inc. reaffirmed a “buy” rating and issued a $201.00 target price (up from $182.00) on shares of Thermo Fisher Scientific in a report on Monday, July 10th. Finally, BidaskClub raised Thermo Fisher Scientific from a “buy” rating to a “strong-buy” rating in a report on Tuesday, July 11th. One analyst has rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $188.56.
In other Thermo Fisher Scientific news, CFO Stephen Williamson sold 2,500 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, June 5th. The shares were sold at an average price of $176.26, for a total value of $440,650.00. Following the completion of the sale, the chief financial officer now owns 37,790 shares of the company’s stock, valued at approximately $6,660,865.40. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Jim P. Manzi sold 1,000 shares of the business’s stock in a transaction on Thursday, August 17th. The shares were sold at an average price of $175.20, for a total transaction of $175,200.00. Following the sale, the director now directly owns 38,757 shares of the company’s stock, valued at approximately $6,790,226.40. The disclosure for this sale can be found here. In the last ninety days, insiders sold 39,506 shares of company stock valued at $6,834,758. 0.49% of the stock is currently owned by insiders.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.